LU90160I2 - Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan - Google Patents

Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan

Info

Publication number
LU90160I2
LU90160I2 LU90160C LU90160C LU90160I2 LU 90160 I2 LU90160 I2 LU 90160I2 LU 90160 C LU90160 C LU 90160C LU 90160 C LU90160 C LU 90160C LU 90160 I2 LU90160 I2 LU 90160I2
Authority
LU
Luxembourg
Prior art keywords
naratriptan
pharmaceutically acceptable
optionally
acceptable salt
hydrochloride
Prior art date
Application number
LU90160C
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878719167A external-priority patent/GB8719167D0/en
Priority claimed from GB888814002A external-priority patent/GB8814002D0/en
Priority claimed from GB888814481A external-priority patent/GB8814481D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of LU90160I2 publication Critical patent/LU90160I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU90160C 1987-08-13 1997-10-31 Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan LU90160I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB878719167A GB8719167D0 (en) 1987-08-13 1987-08-13 Chemical compounds
GB888814002A GB8814002D0 (en) 1988-06-14 1988-06-14 Chemical compounds
GB888814481A GB8814481D0 (en) 1988-06-17 1988-06-17 Chemical compounds

Publications (1)

Publication Number Publication Date
LU90160I2 true LU90160I2 (fr) 1998-01-14

Family

ID=27263551

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90160C LU90160I2 (fr) 1987-08-13 1997-10-31 Naratriptan facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un solvate y compris le chlorhydrate de naratriptan

Country Status (28)

Country Link
US (1) US4997841A (fr)
EP (1) EP0303507B1 (fr)
JP (1) JPH0633252B2 (fr)
KR (1) KR0131327B1 (fr)
AT (1) ATE92057T1 (fr)
AU (1) AU611469B2 (fr)
CA (1) CA1310968C (fr)
CY (1) CY1728A (fr)
CZ (1) CZ404291A3 (fr)
DE (2) DE3882614T2 (fr)
DK (1) DK172696B1 (fr)
ES (1) ES2058292T3 (fr)
FI (1) FI92397C (fr)
GB (1) GB2208646B (fr)
HK (1) HK86793A (fr)
HU (1) HU211576A9 (fr)
IE (1) IE61488B1 (fr)
IL (1) IL87437A0 (fr)
LU (1) LU90160I2 (fr)
LV (1) LV5736B4 (fr)
NL (1) NL970035I2 (fr)
NO (2) NO174052C (fr)
NZ (1) NZ225820A (fr)
PH (1) PH24976A (fr)
PT (1) PT88255B (fr)
SG (1) SG65393G (fr)
SK (1) SK281495B6 (fr)
UY (1) UY23657A1 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds
CZ288351B6 (en) * 1990-06-07 2001-05-16 Astrazeneca Ab Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof
DK152090D0 (da) * 1990-06-22 1990-06-22 Lundbaek A S H Piperidylsubstituerede indolderivater
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
TW222631B (fr) * 1991-07-15 1994-04-21 Duphar Int Res
GB9209882D0 (en) * 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
AU675964B2 (en) * 1992-08-05 1997-02-27 John Wyeth & Brother Limited Amide derivatives
GB9320115D0 (en) * 1993-09-29 1993-11-17 Glaxo Group Ltd Process
US5521196A (en) * 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
FR2731222A1 (fr) * 1995-03-02 1996-09-06 Pf Medicament Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
FR2731224B1 (fr) * 1995-03-02 1997-05-30 Pf Medicament Nouveaux derives bi-tryptaminiques sulfonamides, leur procede de preparation et leur utilisation a titre de medicaments
KR19980703048A (ko) * 1995-03-20 1998-09-05 피터쥐.스트링거 5-치환-3-(1,2,3,6-테트라히드로피리딘-4-일)- 및 3-(피페리딘-4-일)-1h-인돌: 신규한 5-ht1f 아고니스트
AU2104097A (en) * 1996-03-13 1997-10-01 Glaxo Group Limited Medicaments comprising 5ht1-like receptor agonists with an increased absorption
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
MXPA02012927A (es) * 2000-07-21 2003-05-15 Lundbeck & Co As H Derivados de indol utiles para el tratamiento de padecimientos del sistema nervioso central.
WO2002044159A2 (fr) * 2000-11-29 2002-06-06 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine, ses sels acceptables sur le plan pharmaceutique et ses solvants
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
EP2316468A1 (fr) 2002-02-22 2011-05-04 Shire LLC Système de distribution et méthodes de protection et d'administration de dextroamphetamine
EP1644004A4 (fr) 2003-06-20 2010-10-06 Ronald Aung-Din Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes
PL1814538T3 (pl) * 2004-11-24 2010-02-26 Alcon Inc Sposób dostarczania donosowego sprayu
WO2008049116A2 (fr) * 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Indoles substitués
WO2008056378A2 (fr) * 2006-11-09 2008-05-15 Natco Pharma Limited Nouveau procédé destiné à la préparation de naratriptan
WO2008072257A2 (fr) * 2006-12-12 2008-06-19 Ind-Swift Laboratories Limited Procédé de préparation de dérivés de l'indole
WO2009016466A2 (fr) * 2007-07-30 2009-02-05 Orchid Chemicals & Pharmaceuticals Limited Procédé de préparation de chlorhydrate de naratriptan
WO2009118753A2 (fr) * 2008-03-07 2009-10-01 Usv Limited Procédé de préparation de chlorhydrate de naratriptane
CA2729346A1 (fr) 2008-06-30 2010-01-14 Afgin Pharma, Llc Traitement neuro-affectif regional topique
WO2010004580A2 (fr) * 2008-07-11 2010-01-14 Ind-Swift Laboratories Limited Procédé de préparation de dérivés d'indole
WO2010084507A2 (fr) * 2008-07-15 2010-07-29 Sun Pharmaceutical Industries Ltd. Procédé de synthèse du n-méthyl-2-[3-(1-méthyl-4-pipéridyl)-1h-indol-5-yl]-éthanesulfonamide et de ses sels d'addition acide
US8735589B2 (en) 2009-08-20 2014-05-27 Cipla Limited Process for the synthesis of naratriptan
CN102276581B (zh) * 2011-08-05 2013-06-12 上海师范大学 N-取代四氢吡啶连吲哚类化合物及其制备方法及应用
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
BR112017018944A2 (en) 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
EP3766483A1 (fr) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Composition de poudre orodispersible comprenant un triptane

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2362628A1 (fr) * 1976-08-26 1978-03-24 Roussel Uclaf Nouveaux derives du piperidyl-indole et leurs sels, procede de preparation et application a titre de medicaments
FR2421899A1 (fr) * 1978-01-16 1979-11-02 Roussel Uclaf Nouveaux derives du tetrahydropyridinyl-indole et leurs sels, le procede de preparation et l'application a titre de medicaments de ces nouveaux produits
GR79215B (fr) * 1982-06-07 1984-10-22 Glaxo Group Ltd
FR2533924A1 (fr) * 1982-10-05 1984-04-06 Roussel Uclaf Nouveaux derives du 4-(1h-indol-3-yl)a-methyl piperidine-1-ethanol, leurs sels, le procede de preparation, l'application a titre de medicaments et les compositions les renfermant
GB8332437D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
GB8332435D0 (en) * 1983-12-06 1984-01-11 Glaxo Group Ltd Chemical compounds
DE3419935A1 (de) * 1984-05-28 1985-11-28 Merck Patent Gmbh, 6100 Darmstadt Verwendung von hydroxyindolderivaten bei der senkung des blutdrucks
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
US4785016A (en) * 1984-12-04 1988-11-15 Glaxo Group Limited Indole derivatives
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
GB8903036D0 (en) * 1989-02-10 1989-03-30 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CY1728A (en) 1994-05-06
CZ404291A3 (en) 1993-04-14
LV5736B4 (lv) 1997-06-20
SK404291A3 (en) 2000-09-12
JPH0633252B2 (ja) 1994-05-02
AU2069288A (en) 1989-02-16
KR890003731A (ko) 1989-04-17
PT88255A (pt) 1989-06-30
IE882477L (en) 1989-02-13
DE3882614D1 (de) 1993-09-02
GB2208646A (en) 1989-04-12
DK455488A (da) 1989-02-14
DK172696B1 (da) 1999-05-31
NO174052B (no) 1993-11-29
NO883587D0 (no) 1988-08-12
EP0303507A3 (en) 1990-09-19
DE3882614T2 (de) 1993-11-18
KR0131327B1 (en) 1998-04-17
LV5736A4 (lv) 1996-06-20
GB2208646B (en) 1991-06-26
CA1310968C (fr) 1992-12-01
FI92397C (fi) 1994-11-10
EP0303507A2 (fr) 1989-02-15
FI92397B (fi) 1994-07-29
HK86793A (en) 1993-08-27
PH24976A (en) 1990-12-26
NO1998008I1 (no) 1998-02-05
NO174052C (no) 1994-03-09
PT88255B (pt) 1995-03-01
IL87437A0 (en) 1989-01-31
DK455488D0 (da) 1988-08-12
ES2058292T3 (es) 1994-11-01
US4997841A (en) 1991-03-05
FI883744L (fi) 1989-02-14
SK281495B6 (sk) 2001-04-09
NL970035I2 (nl) 1998-01-05
FI883744A0 (fi) 1988-08-12
NZ225820A (en) 1990-09-26
GB8819200D0 (en) 1988-09-14
AU611469B2 (en) 1991-06-13
ATE92057T1 (de) 1993-08-15
UY23657A1 (es) 1994-02-25
EP0303507B1 (fr) 1993-07-28
JPH01207288A (ja) 1989-08-21
IE61488B1 (en) 1994-11-02
NL970035I1 (nl) 1997-11-03
HU211576A9 (en) 1995-12-28
DE19775082I2 (de) 2006-04-27
NO883587L (no) 1989-02-14
SG65393G (en) 1993-08-06

Similar Documents

Publication Publication Date Title
NO1998008I1 (no) Naratriptan
DK391289A (da) Indolderivater
ATE103812T1 (de) Zusammensetzung zur behandlung von ischaemischen stoerungen in organen.
YU177888A (en) Process for preparing new derivatives of benzimidazolin-2-oxo-1-carboxylic acid
CA2203274A1 (fr) Inhibiteurs de synthese d&#39;apolipoproteines-b
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
MY132062A (en) Apolipoprotein-b synthesis inhibitors
IL106445A0 (en) 4-substituted 1,2,4-triazole derivatives,their preparation and pharmaceutical compositions containing them
EP0555479A4 (fr)
PT91613A (pt) Process for the preparation of antihypertensive 3-piperidinyl-indazole derivatives
MY103509A (en) Indole derivatives.
TNSN93081A1 (fr) Procede de preparation de derives de la n-(phenylethyl-b-ol) amine